LDHA and acute myeloid leukemia: The main reason that the ALDH1 role in drug resistance of AML has not been addressed in the clinic, is the prevalence of AML cells with low ALDH1 activity, which made it difficult to understand the dynamic nature of ALDH impact during disease progression.